Clinical Research Professor — Non-Malignant Hematology
Fred Hutch
Seattle (WA)
On-site
USD 318,350 - 396,745
Full time
14 days+
Application generator
A complete application in a minute — tailored resume and cover letter, ready to send.
Get past ATS filters
Benefits offered by this job
Comprehensive benefits package
Paid vacation (22 days per year)
Paid sick leave (up to 30 days)
Paid parental leave (up to 4 weeks)
Relocation assistance or sign-on bonus possible
Job summary
A leading cancer research center in Seattle seeks an Assistant or Associate Professor in Non-Malignant Hematology. The role involves contributing to clinical care, engaging in teaching, and developing individual clinical research programs. Candidates must have an MD/DO degree, board certification in Hematology, and a strong interest in hematology oncology. The position offers comprehensive benefits, and competitive salary ranging from $318,350 to $396,745 depending on rank. Start date is flexible for January 2026.
Qualifications
Record of primary interest in hematology oncology.
Focus on non-malignant hematologic disorders.
Eligibility for medical licensure in Washington.
Responsibilities
Contribute to clinical care and clinical research.
Engage in teaching and oversight of practice providers.
Develop and conduct own clinical research programs.
Skills
Clinical research interest
Experience in non-malignant hematology
Peer-reviewed publications
MD/DO degree or equivalent
Board certification in Hematology
Education
MD/DO degree (or foreign equivalent)
Job description
A leading cancer research center in Seattle seeks an Assistant or Associate Professor in Non-Malignant Hematology. The role involves contributing to clinical care, engaging in teaching, and developing individual clinical research programs. Candidates must have an MD/DO degree, board certification in Hematology, and a strong interest in hematology oncology. The position offers comprehensive benefits, and competitive salary ranging from $318,350 to $396,745 depending on rank. Start date is flexible for January 2026.